Transplantation of IFN-γ Primed hUCMSCs Significantly Improved Outcomes of Experimental Autoimmune Encephalomyelitis in a Mouse Model
- 14 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurochemical Research
- Vol. 45 (7), 1510-1517
- https://doi.org/10.1007/s11064-020-03009-y
Abstract
S The aim of this study was to investigate potential therapeutic effects of IFN-γ primed human umbilical cord mesenchymal stem cell (IFN-γ-hUCMSCs) transplantation on experimental autoimmune encephalomyelitis (EAE) in mice. In this study, EAE mouse model was established by MOG35-55 immunization method. Outcomes of the EAE mice in terms of body weight and clinical symptoms were analyzed. Electromyography (EMG) was performed to evaluate nerve conduction. ELISA was applied to quantify inflammatory cytokine levels in serum. Our results showed that IFN-γ could up-regulate protein expression of indoleamine 2, 3-dioxygenease 1 (IDO1), an important molecule released by MSCs to exert their immune suppressive activity (p < 0.01). In this study treatment efficacy for EAE was compared between transplantation of hUCMSCs alone and the IFN-γ-hUCMSCs which were cultured in the presence of IFN-γ for 48 h prior to be harvested for transplantation. Compared with hUCMSCs alone and control (PBS transfusion) group, transplantation of the IFN-γ-hUCMSCs could significantly alleviate the body weight loss and clinical symptoms of EAE mice (p < 0.05). Consistently EMG latency was significantly improved in treatment groups (p < 0.001), and the IFN-γ-hUCMSCs group was even better than the hUCMSCs group (p < 0.05). Moreover, the concentrations of IL-17A and TNF-α in serum of the mice treated by IFN-γ-hUCMSCs were significantly lower than hUCMSCs alone and controls, respectively (p < 0.05). In few of the roles of IL-17A and TNF-α in the pathogenesis of EAE, IFN-γ-hUCMSCs treatment associated-suppression of IL-17A and TNF-α expression may contribute in part to their therapeutic effects on EAE. In sum, our study highlights a great clinical potential of IFN-γ-hUCMSCs for multiple sclerosis (MS) treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81870848)
- Rong Xiang Regenerative Medicine Foundation
- Youth Talent Fund of the Second Hospital of Shandong University (2018YT37)
This publication has 26 references indexed in Scilit:
- An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosisBrain and Behavior, 2015
- Interferon-Gamma Modification of Mesenchymal Stem Cells: Implications of Autologous and Allogeneic Mesenchymal Stem Cell Therapy in AllotransplantationStem Cell Reviews and Reports, 2014
- Human MSC Suppression Correlates With Cytokine Induction of Indoleamine 2,3-Dioxygenase and Bystander M2 Macrophage DifferentiationMolecular Therapy, 2012
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)British Journal of Pharmacology, 2011
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cellsNature Immunology, 2011
- Immunomodulatory properties of mesenchymal stromal cellsBlood, 2007
- Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammationNature Medicine, 2007
- IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAEJournal of Neuroimmunology, 2006
- Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosisNature, 2003
- THE DEVELOPMENT OF FIBROBLAST COLONIES IN MONOLAYER CULTURES OF GUINEA‐PIG BONE MARROW AND SPLEEN CELLSCell Proliferation, 1970